Skip to main content

Advertisement

Springer Nature is making Coronavirus research free. View research | View latest news | Sign up for updates

Trends in targeted prostate brachytherapy: from multiparametric MRI to nanomolecular radiosensitizers

Cancer Nanotechnology volume 7, Article number: 6 (2016) Cite this article

Abstract

The treatment of localized prostate cancer is expected to become a significant problem in the next decade as an increasingly aging population becomes prone to developing the disease. Recent research into the biological nature of prostate cancer has shown that large localized doses of radiation to the cancer offer excellent long-term disease control. Brachytherapy, a form of localized radiation therapy, has been shown to be one of the most effective methods for delivering high radiation doses to the cancer; however, recent evidence suggests that increasing the localized radiation dose without bound may cause unacceptable increases in long-term side effects. This review focuses on methods that have been proposed, or are already in clinical use, to safely escalate the dose of radiation within the prostate. The advent of multiparametric magnetic resonance imaging (mpMRI) to better identify and localize intraprostatic tumors, and nanomolecular radiosensitizers such as gold nanoparticles (GNPs), may be used synergistically to increase doses to cancerous tissue without the requisite hazard of increased side effects.

Background

Recent studies of the radiobiological properties of prostate cancer cells demonstrate a low alpha/beta ratio; this suggests that hypofractionation—the delivery of larger radiation doses in a smaller number of treatment cycles—may offer the best chance of long-term disease control for localized prostate cancer (Brenner and Hall 1999; Brenner et al. 1998; Vogelius and Bentzen 2013; Carbrera and Lee 2013; Sanfilippo and Cooper 2014). Brachytherapy (BT), the temporary or permanent implantation of small, gamma-emitting radioactive sources directly within cancerous tissue, is a highly effective method for delivering extremely hypofractionated radiation to the prostate (Sanfilippo and Cooper 2014; Yoshioka et al. 2011; Ritter et al. 2011; Tselis et al. 2013). The proximity of the radioactive sources to the cancerous lesions, as well as their placement interstitially within the prostate gland, ensures that the radioactive sources move with the organ, thereby limiting the impact of organ motion on the accuracy of the treatment compared to external beam radiation therapy (EBRT). This phenomenon, along with the rapid dose fall-off beyond the edge of the prostate, enables improved, localized dose escalation (Lee 2009). Several clinical studies demonstrate excellent long-term biochemical disease control rates across risk groups, for both permanent and temporary brachytherapy, and either alone or in combination with EBRT or androgen deprivation therapy (ADT) (Tselis et al. 2013; Ishiyama et al. 2014; Martinez et al. 2010; Morris et al. 2015a, b; Hoskin 2012). A biochemical control and metastasis-free survival rate at 5 years of 94 and 98 %, respectively, was shown by Tselis et al. 2013who evaluated 351 localized prostate cancer patients treated with high-dose-rate (HDR) brachytherapy (Tselis et al. 2013). Preliminary results demonstrated by the large multi-institutional ASCENDE-RT trial show similar long-term control for BT as a boost treatment with EBRT (Morris et al. 2015a, b). In addition to long-term survival benefits, BT also offers significant quality-adjusted life-years (QALYs) benefits over both EBRT alone and radical prostatectomy (RP), the surgical removal of the prostate (Hayes 2010; Steuten and Retel 2013). As a result of the significant benefits of delivering dose-escalated brachytherapy, it has been routinely recommended, either alone or in combination with other treatment modalities, for the treatment of organ-confined disease by the American Brachytherapy Society (ABS), as well as the Groupe Européen de Curithérapie (GEC), and the European Society for Radiotherapy and Oncology (ESTRO) (Davis et al. 2012; Yamada et al. 2012; Hoskin et al. 2013).

Despite the many advantages BT offers, there is growing evidence that increasing radiation doses, without improving dose conformity or targeting accuracy, results in unacceptable patient toxicities (Tselis et al. 2013; Morris et al. 2015a, b; Helou et al. 2014). It has been hypothesized that improving the sensitivity and specificity with which radiation is targeted to prostatic lesions through novel imaging and therapeutic modalities may remove this upper limit on allowable dose escalation (Helou et al. 2014). In this regard, the rapidly expanding fields of multiparametric magnetic resonance imaging (mpMRI) and targeted gold nanoparticles (GNPs) are two of the latest methods that hold the most promise for enabling safe dose escalation (Wallace et al. 2013; Ghai and Haider 2015).

Multiparametric MRI has recently emerged as the imaging modality of choice for detection of localized prostate cancer (supplementing the histopathological information provided by ultrasound-guided biopsies) and has become part of the standard of care for the diagnosis, localization, and staging of prostate cancer, largely due to its superior soft tissue contrast and supplementary functional information (Ghai and Haider 2015; Lawrentscuk and Fleshner 2009; Panebianco et al. 2015; Scheenen et al. 2015; Weinreb et al. 2016). The addition of multiple functional imaging sequences to the anatomical information provided by T2-weighted (T2W) static MR images—including diffusion-weighted imaging (DWI), dynamic contrast-enhanced imaging (DCEI), and magnetic resonance spectroscopic imaging (MRSI)—produce a wealth of additional information to aid in the delineation of active disease (Panebianco et al. 2015; Maneti et al. 2014; Verma et al. 2012; DiBiase et al. 2002). More recently, mpMRI has garnered attention in prostate brachytherapy treatment planning, for improving both prostate gland and intraprostatic lesion localization (Gomez-Iturriaga et al. 2016; Marks et al. 2013; Kaplan et al. 2010; Wu et al. 2014; Menard et al. 2004). The advantages provided by co-registering mpMRI with intra-operative transrectal ultrasound (TRUS) within the prostate BT workflow could significantly reduce the current limitations imposed on dose escalation; this review will examine mpMRI with relation to both its diagnostic and target localization potential for BT (Gomez-Iturriaga et al. 2016). Additionally, the development of intra-operative MRI-only workflows for BT will be examined.

The enhancement of the therapeutic ratio for prostate brachytherapy may also be achieved through the use of radiosensitizers to selectively improve radiation dose delivery to cancerous tissue. Targeted gold nanoparticles (GNPs), due to their physical, radiation, and pharmacokinetic properties, are well suited to BT applications with the potential to boost local radiation doses to levels unimaginable with EBRT or conventional BT alone (Ngawa et al. 2013; Lechtman et al. 2013; Arnida and Ghandehari 2010; Babaei and Ganjalikhani 2014). The addition of radiosensitizers to the BT workflow, in combination with the high spatial resolution of MRI, could significantly improve dose escalation while further sparing patients the associated increase in toxicities. The currently available clinical studies and future potential of these novel nanomolecular agents will be examined in a BT framework.

By synergistically combining the improved image guidance of mpMRI, and the selective targeting provided by nanomolecular radiosensitizers, new treatment paradigms within the BT workspace can also be realized. Single-treatment BT with biological doses beyond what is currently achievable, a greater focus on targeting and treatment of intraprostatic lesions or single dominant intraprostatic lesions (DILs), and improvements in focal and salvage therapy are all potential new areas that may see a rapid improvement with adoption of new dose-escalation methods. Many of these novel directions within the BT space will be covered in this review.

The overall goal of this review is to evaluate the current landscape of dose-escalated prostate brachytherapy in its present form and examine ways in which mpMRI guidance and nanoparticle radiosensitization can selectively improve dose escalation in the future. The constantly changing research and clinical landscape of targeted therapy for prostate cancer makes it difficult to perform an exhaustive review on this rapidly evolving field; this review represents only an instance of the literature at the time of publication.

Clinical overview of prostate brachytherapy

The two most common methodologies for delivering hypofractionated radiation for localized prostate cancer are low-dose-rate (LDR) and high-dose-rate (HDR) BT. LDR, or permanent implant BT, involves the permanent placement of 80–100 radioactive substances within the interstitial space of the prostate gland. High-dose-rate (HDR) BT, by comparison, involves the temporary implantation of hollow catheters into the prostate through which a highly radioactive source is remotely passed for a short period of time; the transit time of the source within the catheters determines the magnitude of the delivered dose. Both workflows generally follow a similar planning framework as recommended by both ABS and GEC-ESTRO guidelines (Davis et al. 2012; Yamada et al. 2012; Hoskin et al. 2013). The components of a typical BT patient pathway are as follows: (1) diagnosis of localized prostate cancer, (2) pre-operative or intra-operative treatment planning and treatment delivery, (3) post-implant quality assurance.

Diagnosis using MRI

Traditionally, definitive diagnosis of localized prostate cancer relied on the TRUS-guided sextant biopsy for identification of cancerous tissue; this approach alone was found to leave up to 15 % of cancers undetected and was prone to sampling error (Norberg et al. 1997). The information from TRUS biopsy is now routinely correlated with imaging information provided by multiparametric MRI (mpMRI); this offers a clearer representation of disease foci and extraprostatic disease extension as well as improved biopsy sampling and characterization as part of staging (Lawrentscuk and Fleshner 2009; Kaplan et al. 2002; Cirillo et al. 2008; Pullini et al. 2016). In 2012, the prostate imaging–reporting and data system (PI-RADS v.1, updated in 2015/2016) was developed to standardize the approach to diagnosis and reporting of mpMRI for prostate cancer (Weinreb et al. 2016); several recommendations were made. Diagnosis of prostate cancer should be performed using T2-weighted fast spin echo (T2W-FSE) sequences on a 1.5–3T MRI scanner, the latter being preferred due to its higher signal-to-noise ratio, along with inclusion of functional DCEI, DWI, and potentially MRSI sequences. A high degree of visibility of the prostate peripheral zones, along with urethral and rectal structures, seminal vesicles, and prostatic capsule (extra- and intracapsular disease) is typically required. Each imaging sequence of the mpMRI acquisition contributes supplementary information that facilitates diagnosis and/or staging of localized disease; the PI-RADS reporting system further standardizes this approach according to the respective imaging sequence.

T2W-FSE images (see Table 1 for recommended PI-RADS parameters) are typically used to discriminate between zonal anatomies of the prostate and discern normal tissue from various abnormalities; however, a number of benign conditions may mimic the T2W appearance of prostate cancer including benign prostatic hyperplasia (BPH) or prostatitis (Kitajima et al. 2010). Intraprostatic cancerous tissue conversely may also be difficult to detect on this imaging alone; Fig. 1 shows a typical example of a multiplanar T2W-FSE image of the prostate and surrounding anatomy. The limitations of purely anatomic imaging necessitate the supplementary use of functional imaging sequences.

Table 1 PI-RADS recommendations for mpMRI sequence parameters
Full size table
Fig. 1
figure1

Multiplanar T2-weighted fast-spin echo (T2W-FSE) images (axial, coronal, and sagittal midplanes) of a patient with localized prostate cancer treated with EBRT (45 Gy/25), followed by an HDR BT boost (15 Gy/1). The prostate (purple) and dominant intraprostatic lesion (light blue) are not readily visible without supplementary functional imaging

Full size image

DWI, a functional method of measuring random water molecule diffusion rates within tissue, is typically used to supplement T2W-FSE acquisitions. Prostate cancers present with restricted diffusion rates relative to the surrounding normal prostatic tissue, a phenomenon that is represented through apparent diffusion coefficient (ADC) maps computed at each image voxel (Weinreb et al. 2016; Kim et al. 2010). B values—an indicator of the rate of diffusion that is captured by the image dataset—have recommended ranges between 0 and 1000 s/mm2; larger b values are used to detect slower diffusion rates of water molecules (Kim et al. 2010). The inclusion of DWI sequences with T2W imaging improves detection of prostate cancer, particularly in the peripheral zone tumors (Haider et al. 2007). Figure 2 shows a typical DWI axial sequence of the prostate.

Fig. 2
figure2

Diffusion-weighted imaging (DWI) of an axial midgland plane with high b value ADC map. Areas of higher water diffusion rates appear brighter on T2 imaging. Significant cancers may present with restricted diffusion rates and are seen as areas of hypointense signal on the ADC map (arrow). The focal lesion is contoured for clarity

Full size image

DCEI obtained by acquiring T1W image sequences during administration of an intravenous gadolinium-based contrast agent (GBCA), is used to further supplement the information obtained from both T2W and DWI sequences. DCEI takes advantage of cancer angiogenesis, a process that increases vascular density and permeability within tumors, to visualize prostatic regions of increased uptake of the GBCA (Verma et al. 2012; Singanamalli et al. 2016). Figure 3 shows the differential uptake of GBCA within areas of active tumor (the DIL), over a set of sequential axial frames. The addition of DCEI to the mpMRI sequence has demonstrated improvements in sensitivity and lesion detection accuracy (Kitajima et al. 2010; Alonzo et al. 2016).

Fig. 3
figure3

Axial midgland sequence showing dynamic contrast-enhanced imaging (DCEI) acquired using T1W-FSE sequences over a 1 min period. Gadolinium-based contrast agent (GBCA) is administered intravenously at an injection rate of 2–3 cc per second; lesion enhancement may appear as early as 10 s following injection. Enhancement of the DIL is shown in frames 4 through 7 (arrows), followed by a washout phase where the signal dissipates

Full size image

Magnetic resonance spectroscopic imaging (MRSI), while not as widely adopted as DWI or DCEI, is gaining interest as a valuable technique for non-invasively determining the biochemical concentrations of biomarkers associated with prostate cancer (Kurhanewicz et al. 2002; Picket et al. 2004; Pouliot et al. 2004). MRSI may be more specific in differentiating benign conditions from actively metabolic prostate cancer and may provide metabolic information associated with tumor progression (Kobus et al. 2014). In vivo prostate MRSI utilizes the relative or absolute concentrations of the metabolites such as choline, polyamines, creatine and citrate, as cancer specific biomarkers, with 98 % of cancers demonstrating an elevated (choline + creatine)/citrate ratio greater than the ratio for normal tissue (Fig. 4) (Westphalen et al. 2008; Scheenen et al. 2015). Addition of the functional information provided by MRSI could potentially improve diagnosis, staging, and disease localization for BT. The diagnostic value of combined magnetic resonance imaging and spectroscopic techniques has encouraged radiologists and oncologists to include it increasingly for clinical use.

Fig. 4
figure4

Magnetic resonance spectroscopic imaging (MRSI) spectra obtained using a conformal voxel approach for areas of normal tissue (green voxel), and suspected abnormality (red voxel) and for short (TE = 40 ms), and long (TE = 130 ms) echo times. A spectral-spatial RF pulse sequence was used. In a normal voxels are displayed demonstrating the appearance of short TE metabolites (i.e., sI—scyllo-inositol) not evident at longer echo times. Similarly, in b there is a decrease in relative concentration of citrate to choline over voxels with suspected cancer

Full size image

Pre- and intra-operative image guidance and treatment planning

Once diagnosis and staging of prostate cancer have been completed (and BT is selected as a treatment option), the identification of critical target and normal tissue structures is made. During this phase, the target, typically the entire prostate gland and/or focal lesions, and organs at risk (OARs) are identified for treatment planning (Thomadsen et al. 2012; Yu et al. 1999). Historically, CT, TRUS, and more recently mpMRI, have been used to identify critical structures (Nath et al. 2009; Metcalfe et al. 2013; Rischke et al. 2013). Clinical use of CT or TRUS has traditionally been the mainstay of pre-treatment imaging for target identification, but recent improvements in the availability of diagnostic MRI scanners have improved access significantly to mpMRI for this purpose (Davis et al. 2012; Yamada et al. 2012; Nag et al. 2000; Mayer et al. 2016). Several studies have pointed to the subjectivity of contouring on conventional imaging modalities. Better imaging methods are being heralded as a means to provide objectivity to this aspect of the planning process (Rischke et al. 2013; Steenbergen et al. 2015; Fiorino et al. 1998).

Pre-operative guidance prior to MRI

CT-guided BT planning represents one of the earliest attempts to use volumetric imaging to accurately identify targets and OARs, as well as plan radioactive source positions, with good outcomes; Koutrouvelis et al. (2000) reported prostate-specific antigen (PSA) <2 ng/mL in 90 % of patients (n = 301) at median 26 month follow-up after being treated with permanent implant CT-guided BT (Koutrouvelis et al. 2000). Intra-operative TRUS-guided BT is rapidly growing in adoption largely due to its lower cost, widespread availability, and real-time guidance, and has allowed implant guidance during the BT procedure in addition to target localization. Stone et al. (2007), pioneers of the TRUS-guided permanent implant approach, reported excellent long-term toxicity outcomes of 325 patients (Stone and Stock 2007; Crook et al. 2011). TRUS-guided BT is now the recommended standard of care for prostate BT by both ABS and GEC-ESTRO guidelines for both LDR and HDR implants (Davis et al. 2012; Yamada et al. 2012; Hoskin et al. 2013). Despite these many advantages, significant TRUS artifact still make identification of the target and OARs highly subjective (Fig. 5) (Xue et al. 2006; Solhjem 2004). Further identification of DILs for dose escalation is simply not feasible using TRUS guidance alone, and a workflow incorporating mpMRI fusion with TRUS imaging is commonly required.

Fig. 5
figure5

TRUS axial, coronal, and sagittal midgland planes for a patient treated with TRUS-guided HDR BT. The live TRUS images were co-registered with the contours obtained from mpMRI to yield the prostate (red) and DIL (light blue) contours. The difficulty in identifying distal catheters compared to proximal catheters is also apparent (arrows)

Full size image

Pre-operative MRI for treatment planning

MRI, in addition to its diagnostic capability, has been recognized as the ideal imaging modality for soft tissue prostate delineation, as well as for discrimination of nearby normal tissues (Dinh et al. 2016). Using the information obtained from mpMRI radiation, oncologists can identify the prostate, focal lesions, and nearby healthy tissues (urethra and rectum, commonly) with greater confidence than using TRUS or CT imaging.

However, since the information from mpMRI is typically only available in a pre-operative setting, an additional imaging modality must be co-registered to obtain contours of the target and OARs during the planning stage. Following an initial pre-treatment mpMRI the dataset is co-registered with live intra-operative TRUS, a technique adapted from advances in TRUS-guided biopsies (Kaplan et al. 2002; Marks et al. 2013). Delineated contours from the mpMRI are then propagated onto the live TRUS images; this approach has allowed improved targeting of the prostate, and even potentially DILs, without altering the intra-operative imaging modality (DiBiase et al. 2002; Marks et al. 2013; Crook et al. 2014). Unilateral focal disease has been treated using DCE imaging to contour the DIL with the intent of focal dose escalation. Images from the mpMRI were transposed onto the intra-operative TRUS. An average of 20–30 % dose escalation to the DIL was feasible using this approach (Crook et al. 2014). More recently, Gomez-Iturriaga et al. (2016) were able to treat 15 patients with a single MR-TRUS-guided HDR boost of 15 Gy; the DIL was treated to 18.75 Gy. At a median follow-up of 18 months, none of the patients developed grade ≥3 urinary toxicity (Gomez-Iturriaga et al. 2016). Although registration errors may occur due to the imperfect correlation of MRI to live TRUS imaging, many commercially available deformable registration algorithms have been developed to improve this process and are a growing area of interest (Sparks et al. 2013). Target and OAR identification continue to pose a challenge for mpMRI-fused BT workflows; as a result, the use of intra-operative MRI guidance for BT has garnered significant interest in an attempt to alleviate this problem.

Intra-operative guidance prior to MRI

Current GEC-ESTRO and ABS guidelines for prostate brachytherapy recommend intra-operative TRUS imaging for visualization of the prostatic capsule, nearby anatomy, and implant guidance. Interpretation of TRUS images is highly subjective, leading to difficulties in target, OAR, and source identification during implantation. Figure 5 outlines some of the difficulties in identification of catheter trajectories for an HDR prostate BT procedure. For HDR BT, once catheter identification has been completed, an optimization algorithm is used to determine the optimal dwell times of the radioactive source within each catheter with the goal of maximizing the radiation dose to the target(s) while minimizing the dose to normal tissues (Fig. 6). A similar process in LDR BT is used to determine the configuration of implanted sources within the prostate gland.

Fig. 6
figure6

Typical HDR prostate BT treatment plan showing axial midgland plane for a patient treated with 19 Gy. Twelve catheters (hyperechoic regions) were implanted and dwell times optimized using Oncentra Prostate (Elekta AB, Stockholm, Sweden). The organ contours are the prostate (red), urethra (light blue), focal lesion (light teal), and rectum (dark brown). The isodose lines are represented as a percentage of the prescription dose (arrows)

Full size image

Intra-operative guidance using MRI

The use of intra-operative MRI guidance for prostate brachytherapy arose from earlier iterations with interventional TRUS biopsies performed in both open and closed-bore MRI scanners (D’Amico et al. 2000; Tokuda et al. 2012). When applied to both LDR and HDR brachytherapy, this approach enabled the monitoring of implanted sources and/or needles with respect to the soft tissue boundaries of the prostate and normal tissues. These workflows typically mimic current intra-operative BT workflows using TRUS guidance. Prostate or DIL identification is done by a radiologist in the MRI interventional suite with the patient anesthetized in the scanner bore. Intra-operative approaches to MRI-guided BT involving low-field (0.2–0.5 T) (Cormack et al. 2000; Ares et al. 2009) and high-field closed-bore (1.5–3 T) (Menard et al. 2004; Susil et al. 2004) have been evaluated clinically with encouraging early results. Low-field, open-bore systems offer improved interventional access to the patient, but at the cost of decreased imaging quality due to the lower field strength; additionally, the low field strength significantly limits application of DCE imaging and other functional techniques. Higher field strength, closed-bore magnets, although creating challenges for interventional approaches due to the limited access to the patient, offers superior image quality and are more readily available in clinical settings (as 1.5 or 3 T units).

The intra-operative workflow outlined by Menard et al. (2004) is an excellent example of an MRI-dedicated HDR workflow using a closed-bore, high-field strength (1.5 T) MRI (Menard et al. 2004). Patients were placed in the left lateral decubitus position into the scanner bore and anesthetized using general anesthesia. An endorectal coil was inserted to improve visualization of the pelvic anatomy and scout MRI images were obtained to localize the treatment site. Catheters (with metallic, MR-safe obturators) were implanted by removing the scanner table from the scanner isocenter, inserting the catheter, advancing the table back to the isocenter, and then re-acquiring FSE sequences to evaluate the catheter positions (on both axial and sagittal planes). Early clinical results have been promising; however, the limitations of the closed-bore procedure increase the procedure time significantly over the current standard TRUS-guided techniques (Menard et al. 2004; Ares et al. 2009).

Post-implant quality assurance

Typically, post-implant dosimetry is performed 1 month after an LDR BT implant using CT guidance (Fig. 7); the position of the implanted sources are identified, along with normal tissues and target volumes, and the isodose distribution is recomputed to evaluate the quality of the delivered treatment (Potters et al. 2001). Post-operative dosimetry metrics have been poorly correlated with intra-operative dosimetry; a study by Acher et al. (2010) showed that this was largely due to the subjective nature of the contoured prostate volume on CT (Merrick et al. 1999; Acher et al. 2010). MRI-based post-implant dosimetry has been proposed to offer improved discrimination between the prostate and OARs; however, signal voids around the metallic casings of brachytherapy sources pose a challenge for accurate source localization. Thomas et al. (2009) demonstrated that signal voids surrounding brachytherapy sources exist for increasing field strengths (3–4.5 mm separation for 1.5 T, and 4.5–6 mm for 3 T), which affect the accuracy with which the sources are localized; a proton density-weighted FSE sequence was used to limit this effect with good results (Thomas et al. 2009). Various studies demonstrated techniques to minimize these artifacts; Kuo et al. (2010) examined an in-phantom method using inversion recovery with ON-resonant suppression (IRON) to generate positive contrast in areas of high magnetic susceptibility artifact (Kuo et al. 2010). Similarly, positive contrast agents such as cobalt dichloride-N-acetyl-cysteine (C4) have been used as encapsulated markers and show promise at a number of different parameters and field strengths, without altering the dosimetry of the delivered therapy, and showing minimal patient toxicities (Lim et al. 2014; Frank et al. 2008).

Fig. 7
figure7

Post-implant dosimetric quality assurance (QA) for a typical LDR BT treatment plan 1 month following implantation. Imaging the prostate (red) and rectum (blue) interface can be challenging on CT-guided post-implant QA. Isodose lines are shown as a percentage of the prescription dose (145 Gy). Sources are identified as green circles with upward-directed and downward-directed triangles representing out-of-plan sources. Treatment planning system is VariSeed 8.0 (Varian Inc. Palo Alto, CA, USA)

Full size image

The future of targeted prostate brachytherapy

The advent of targeted imaging and treatment techniques has spawned interest in novel brachytherapy planning methodologies. The use of mpMRI for improved prostate and DIL localization may shift the focus of treatment to preferentially target focal lesions with higher radiation doses, while reducing doses to surrounding normal tissues. In addition to the improved localization offered by mpMRI, novel radiosensitizing nanoparticles have recently gained popularity as a method to selectively boost the dose of radiation to focal lesions beyond conventional means while maintaining normal tissue toxicities at current levels.

Focal and salvage therapy using MRI guidance

Traditionally, the use of CT and TRUS guidance for prostate BT planning was limited to treating the entire gland, largely due to the inability to resolve the multifocal nature of intraprostatic disease with confidence. The significant improvement in the ability to differentiate individual focal lesions using mpMRI enables targeted dose escalation, while decreasing the whole-gland dose, thereby significantly reducing the dose to the OARs (Muller et al. 2014; Crehange et al. 2014).

Studies evaluating focal boosting to both single and multifocal DILs using both LDR and HDR have emerged recently. Ahmed et al. (2012) showed excellent 12 month outcomes and urinary toxicity following LDR BT focal boost (Ahmed et al. 2012). Banerjee et al. (2015) and Gomez-Iturriaga et al. (2016) demonstrated similar results with HDR BT showing significant escalation of DIL doses without an expected increase in urinary toxicities (Gomez-Iturriaga et al. 2016; Banerjee et al. 2015). This approach has also shown promise in focal salvage therapy, using both LDR and HDR, in reduction of urinary toxicities while maintaining excellent outcomes comparable to whole-gland salvage treatment (Hsu et al. 2013; Duijzentkunst et al. 2016).

These promising hypothesis-generating studies require robust long-term control and toxicity data, but they do indicate that focal boosting (and focal salvage therapy) using mpMRI-guided HDR and LDR is a feasible method for dose escalation while minimizing OAR toxicities.

There exist ample opportunities for multimodality fusion of mpMRI as well as intra-operative MRI for focal dose escalation. Significant technological hurdles to the implementation of intra-operative MRI-guided BT make it more likely that multimodality fusion will be readily adopted as a means to deliver focal or whole-gland BT. For centers that have the ability to implement intra-operative guidance for BT, it is likely that closed-bore, high-strength MRIs will see increased uptake due to their wider availability and ability to deliver high-quality anatomical and functional imaging.

Radiosensitization using gold nanoparticles

Another promising new technique for improving local dose escalation, potentially acting synergistically with the improved image guidance afforded by mpMRI, is the use of gold nanoparticles (GNP) for selective radiosensitization of tumors (Jain et al. 2012; Babaei and Ganjalikhani 2014). The main mechanism of action of these nanoparticles is the production of photo- and Auger electrons by the photoelectric effect after bombardment with photons (Spiers 1949; Castillo et al. 1988). The short range of these electrons requires that cytosolic uptake of GNPs occurs to create DNA single- and double-strand breaks (Zheng et al. 2008). The selective dose enhancement factor (DEF)—the increased effect of local radiation dose deposition due to the GNPs—has been observed with high GNP concentrations in conjunction with keV photon energies as outlined by Zhang et al. 2008, Rahman et al. (2009) and Roeske et al. (2007). The introduction of GNP-mediated radiosensitization both for LDR and HDR brachytherapy, which emit gamma photon energies in the ideal range for maximizing DEF, holds significant promise.

Due to the long half-life of most LDR brachytherapy sources, GNPs introduced into cancerous cells must remain within the cell cytosol for extended periods of time to sufficiently provide a dose-enhancement effect. Shorter periods of GNP uptake by prostate cancer cells may be suitable for HDR delivery, due to the rapid radiation delivery (in the order of 10–30 min), and it therefore may serve as an easier pathway to GNP integration within the BT framework. Further development and customization of GNPs to specifically tailor them for use in prostate BT should focus on the route of administration, pharmacokinetics, and cellular uptake.

The geometric and functional parameters of GNPs play an important role in their uptake as outlined in Albanese et al. (2012), Perrault et al. (2009) and Favi et al. (2015). Naïve GNPs without additional ligands preferentially accumulate at sites of porous and leaky tumor vasculature (Jain et al. 2012). The addition of ligands such as polyethylene glycol (PEG) allow improved non-specific uptake by receptor-mediated endocytosis (RME) within tumors, as well as improved transit times in systemic circulation (Zhang et al. 2008; Kumar et al. 2013; Lechtman et al. 2013; Chithrani et al. 2006). Further functionalization by addition of tumor-specific ligands may enable GNPs to further target prostate cancer with increased specificity. Of importance in uptake and clearance is GNP size: smaller GNPs tend to have rapid circulations when administered intravenously and are quickly cleared by the renal system but more rapidly permeate tumor vasculature, while excessively large particles may have significantly increased uptake by the Reticuloendothelial System (RES), a process which decreases selective DEF (Arnida and Ghandehari 2010; Maeda et al. 2001).

In contrast to systemic administration, the intra-operative nature of BT procedures may enable interstitial injection of GNPs directly within focal lesions outlined on mpMRI. In this proposed workflow, the pre-treatment mpMRI-TRUS—or intra-operative MRI—could be used to localize focal lesions and the high spatial resolution of MRI could be used to guide deposition of high concentrations of GNPs directly within these cancerous foci during the BT procedure. This approach may significantly reduce the need for larger GNP sizes with their increased residence time, thereby taking advantage of the benefits of small GNP sizes. Evidence suggests that a medium range (6–50 nm) PEGylated, spherical GNP, administered interstitially, could allow sufficient tumor uptake and retention over the course of LDR BT to offer a significant dose-enhancement effect (Chithrani et al. 2006). For HDR BT, a smaller size (<6 nm) PEGylated, spherical GNP may be more suitable, allowing for a residence time and dispersion that correlated with the procedure duration, thereby producing the required dose enhancement with fewer potential side effects. GNPs could be administered during the procedure and rapidly cleared from circulation afterward. Commercially available GNPs specifically optimized for radiation therapy are also being developed to have longer circulation, small sizes (2–3 nm), higher tumor uptake, and improved clearance (Kumar et al. 2013). It remains to be seen if the pharmacokinetics of these commercially available GNPs is similar when administered locally within the prostate gland.

Conjugation of gadolinium with GNPs (Gd-GNP) could also allow for visualization on intra-operative MRI and offer a means of calculating the biological effective dose from the additive effects of GNPs during HDR BT (Harisinghani et al. 2003; Debouttiere et al. 2006; Le Duc et al. 2014). Vartholomeos et al. 2011 also examined the use of MRI-compatible nanoparticles to act as drug-delivery nanorobots under MRI-guided steering; similar methodologies may be applied to both track and steer injected GNPs to tumor vasculature within the prostate gland during BT (Vartholomeos et al. 2011).

There remain significant challenges with local deposition of high GNP concentrations within the prostate gland largely relating to their diffusion and uptake within the tumor vasculature. The assumption of homogenous GNP distribution with local administration may not be accurate, especially with local administration; problems with inconsistent tumor vasculature (particularly in hypoxic tumor regions) may cause poor uptake or heterogeneous GNP distribution even within small focal lesions. It is prudent to assume that focal lesions neighboring normal tissues, such as the urethra, may be at risk of excessive local hot spots with uneven GNP distribution and therefore further exploration is needed. Additionally, although systemic toxicities of GNP administration have been noted as minimal in some studies (Alkilany and Murphy 2010; Fratoddi et al. 2014), the examination of toxicities from localized injection of high GNP concentrations within the prostate requires further study if they are to be used in BT.

Conclusions

Although long-term biochemical control and toxicity results of mpMRI-guided BT are forthcoming, it is expected that this method will continue to drive high-precision dose escalation for localized prostate cancer in the near future. The ability to deliver large localized doses to focal lesions within the prostate gland has profound implications for BT as first-line therapy as well as salvage therapy. Inclusion of GNPs to improve the radiosensitivity of prostate cancer is expected to offer additional normal tissue sparing effects and is a promising area of development. Future in-human clinical trials of radiotherapy-specific GNPs may shed some light on the impact these particles will have on prostate cancer.

Abbreviations

ABS:

American brachytherapy society

ADC:

apparent diffusion coefficient

ADT:

androgen deprivation therapy

BPH:

benign prostatic hyperplasia

BT:

brachytherapy

C4:

cobalt dichloride-N-acetyl-cysteine

CT:

computed tomography

DCEI:

dynamic contrast-enhanced imaging

DEF:

dose enhancement factor

DIL:

dominant intraprostatic lesion

DWI:

diffusion-weighted imaging

EBRT:

external beam radiation therapy

GBCA:

gadolinium-based contrast agent

GEC-ESTRO:

Groupe Européen de Curithérapie/European society for radiotherapy and oncology

GNP:

gold nanoparticle

Gy:

gray

HDR:

high-dose-rate brachytherapy

IRON:

inversion recovery with ON-resonant suppression

LDR:

low-dose-rate brachytherapy

mpMRI:

multiparametric magnetic resonance imaging

MRSI:

magnetic resonance spectroscopic imaging

OAR:

organs at risk

PEG:

polyethylene glycol

PI-RADS:

prostate imaging reporting and data system

PSA:

prostate-specific antigen

RES:

reticuloendothelial system

RP:

radical prostatectomy

T:

tesla

T2W/FSE:

T2-weighted MRI/fast-spin echo

TE:

echo time

TR:

repetition time

TRUS:

TransRectal ultrasound

References

  1. Acher P, Puttagunta S, Rhode K, Morris S, Kinsella J, Gaya A, et al. An analysis of intraoperative versus post-operative dosimetry with CT, CT-MR fusion and XMR for the evaluation of prostate brachytherapy implants. Radiother Oncol. 2010;96(2):166–71.

  2. Ahmed HU, Hindley RG, Dickinson L, Freeman A, Kirkham AP, Sahu M, et al. Focal therapy for localized unifocal and multifocal prostate cancer: a prospective development study. Lancet Oncol. 2012;13(6):622–32.

  3. Albanese A, Tang PS, Chan WC. The effect of nanoparticle size, shape, and surface chemistry on biological systems. Annu Rev Biomed Eng. 2012;14:1–16.

  4. Alkilany AM, Murphy CJ. Toxicity and cellular uptake of gold nanoparticles: what we have learned so far. J Nanopart Res. 2010;12(7):2313–33.

  5. Alonzo F, Melodelima C, Bratan F, Vitry T, Crouzet S, Gelet A, et al. Detection of locally radio-recurrent prostate cancer at multiparametric MRI: can dynamic contrast-enhanced imaging be omitted? Diagn Interv Imaging. 2016;97(4):433–41.

  6. Ares C, Popowski Y, Pampallona S, Nouet P, Dipasquale G, Bieri S, et al. Hypofractionated boost with high-dose-rate brachytherapy and open magnetic resonance imaging-guided implants for locally aggressive prostate cancer: a sequential dose-escalation pilot study. Int J Radiat Oncol Biol Phys. 2009;75(3):656–63.

  7. Arnida Malugin A, Ghandehari H. Cellular uptake and toxicity of gold nanoparticles in prostate cancer cells: a comparative study of rods and spheres. J Appl Toxicol. 2010;30(3):212–7.

  8. Babaei M, Ganjalikhani M. The potential effectiveness of nanoparticles as radio sensitizers for radiotherapy. Bioimpacts. 2014;4(1):15–20.

  9. Banerjee R, Park SJ, Anderson E, Demanes DJ, Wang J, Kamrava M. From whole-gland to hemigland to ultra-focal high-dose-rate prostate brachytherapy: a dosimetric analysis. Brachytherapy. 2015;14(3):366–72.

  10. Brenner DJ, Hall EJ. Fractionation and protraction for radiotherapy of prostate carcinoma. Int J Radiat Oncol Biol Phys. 1999;43(5):1095–101.

  11. Brenner DJ, Hlatky LR, Hahnfeldt PJ, Huang Y, Sachs RK. The linear-quadratic model and most other common models results in similar predictions of time-dose relationships. Radiat Res. 1998;150(1):83–91.

  12. Carbrera AR, Lee WR. Hypofractionation for clinically localized prostate cancer. Semin Radiat Oncol. 2013;23(3):191–7.

  13. Castillo MH, Burton TM, Doerr R, Homs MI, Pruett CW, Pearce JI. Effects of radiotherapy on mandibular reconstruction plates. Am J Surg. 1988;156:261–3.

  14. Chithrani BD, Chazani AA, Chan WC. Determining the size and shape dependence of gold nanoparticle uptake in mammalian cells. Nano Lett. 2006;6(4):662–8.

  15. Cirillo S, Petracchini M, Monica PD, Gallo T, Tartaglia V, Vestita E, et al. Value of endorectal MRI and MRS in patients with elevated prostate-specific antigen levels and previous negative biopsies to localize peripheral zone tumours. Clin Radiol. 2008;63(8):871–9.

  16. Cormack RA, Kooy H, Tempany CM, D’Amico AV. A clinical method for real-time dosimetric guidance of transperineal 125I prostate implants using interventional magnetic resonance imaging. Int J Radiat Oncol Biol Phys. 2000;46(1):207–14.

  17. Crehange G, Roach M 3rd, Martin E, Cormier L, Peiffert D, Cochet A, et al. Salvage reirradiation for locoregional failure after radiation therapy for prostate cancer: who, when, where and how? Cancer Radiother. 2014;18(5–6):524–34.

  18. Crook JM, Gomez-Iturriaga A, Wallace K, Ma C, Fung S, Alibhai S, et al. Comparison of health-related quality of life 5 years after SPIRIT: surgical prostatectomy versus interstitial radiation intervention trial. J Clin Oncol. 2011;29(4):362–8.

  19. Crook J, Ots A, Gaztanaga M, Schmid M, Araujo C, Hilts M, et al. Ultrasound-planned high-dose-rate prostate brachytherapy: dose painting to the dominant intraprostatic lesion. Brachytherapy. 2014;13(5):433–41.

  20. D’Amico AV, Tempanay CM, Cormack R, Hata N, Jinzaki M, Tuncali K, et al. Transperineal magnetic resonance image guided prostate biopsy. J Urol. 2000;164(2):385–7.

  21. Davis BJ, Horwitz EM, Lee WR, Crook JM, Stock RG, Merrick GS, et al. American brachytherapy society consensus guidelines for transrectal ultrasound-guided permanent prostate brachytherapy. Brachytherapy. 2012;11(1):6–19.

  22. Debouttiere PJ, Roux S, Vocanson F, Billotey C, Beuf O, Favre-Reguillon A, et al. Design of gold nanoparticles for magnetic resonance imaging. Adv Func Mater. 2006;16:2330–9.

  23. DiBiase SJ, Hosseinzadeh K, Gullapalli RP, Jacobs SC, Naslund MJ, Sklar GN, et al. Magnetic resonance spectroscopic imaging-guided brachytherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2002;52(2):429–38.

  24. Dinh CV, Steenbergen P, Ghobadi G, Hejimink SW, Pos FJ, Haustermans K, et al. Magnetic resonance imaging for prostate cancer radiotherapy. Phys Med. 2016;16:S1120–797.

  25. Duijzentkunst DA, Peters M, van der Voort van Zyp JRN, Moerland MA, van Vulpen M. Focal salvage therapy for local prostate cancer recurrences after primary radiotherapy: a comprehensive review. World J Urol. 2016. (In-Press).

  26. Favi PM, Gao M, Arango LJS, Ospina SP, Morales M, Pavon JJ, et al. Shape and surface effects on the cytotoxicity of nanoparticles: gold nanospheres versus gold nanostars. J Biomed Mat Res. 2015;103(11):3449–62.

  27. Fiorino C, Reni M, Bolognesi A, Cattaneo GM, Calandrino R. Intra- and inter-observer variability in contouring prostate and seminal vesicles: implications for conformal treatment planning. Radiother Oncol. 1998;47(3):285–92.

  28. Frank SJ, Stafford RJ, Bankson JA, Li C, Swanson DA, Kudchadker RJ, et al. A novel MRI marker for prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2008;71(1):5–8.

  29. Fratoddi I, Venditti I, Cametti C, Russo MV. How toxic are gold nanoparticles? The state-of-the-art. Nano Res. 2014;8(6):1771–99.

  30. Ghai S, Haider MA. Multiparametric-MRI in diagnosis of prostate cancer. Indian J Urol. 2015;31(3):194–201.

  31. Gomez-Iturriaga A, Casquero F, Urresola A, Ezquerro A, Lopez JI, Espinosa JM, et al. Dose escalation to dominant intraprostatic lesions with MRI-transrectal ultrasound fusion high-dose-rate prostate brachytherapy. Prospective phase II trial. Radiother Oncol. 2016;119:91–6 (In-Press).

  32. Haider MA, Van der Kwast TH, Tanguay J, Evans AJ, Hashmi AT, Lockwood G, et al. Combined T2-weighted and diffusion-weighted MRI for localization of prostate cancer. Am J Roentgenol. 2007;189(2):323–8.

  33. Harisinghani MG, Barentsz J, Hahn PF, Deserno WM, Tabatabaei S, van deKaa CH, et al. Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med. 2003;348:2491–9.

  34. Hayes HJ, Ollendorf DA, Pearson SD, et al. Active surveillance compared with initial treatment for med with low-risk prostate cancer: a decision analysis. JAMA. 2010;304:2373–80.

  35. Helou J, Morton G, Zhang L, Deabreu A, D’Alimonte L, Elias E, et al. A comparative study of quality of life in patients with localized prostate cancer treated at a single institution: stereotactic ablative radiotherapy of external beam + high dose rate brachytherapy boost. Radiother Oncol. 2014;113:404–9.

  36. Hoskin PJ, Rojas AM, Bownes PJ, Lowe GJ, Ostler PJ, Bryant L. Randomised trial of external beam radiotherapy alone or combined with high-dose rate brachytherapy boost for localized prostate cancer. Radiother Oncol. 2012;103(2):217–22.

  37. Hoskin PJ, Colombo A, Henry A, Niehoff P, Paulsen Hellebust T, Siebert FA, et al. GEC/ESTRO recommendations on high dose rate after loading brachytherapy for localized prostate cancer: an update. Radiother Oncol. 2013;107(3):325–32.

  38. Hsu CC, Hsu H, Pickett B, Crehange G, Hsu IC, Dea R, Weinberg V, et al. Feasibility of MR imaging/MR spectroscopy-planned focal partial salvage permanent prostate implant (PPI) for localized recurrence after initial PPI for prostate cancer. Int J Radiat Oncol Biol Phys. 2013;85(2):370–7.

  39. Ishiyama H, Satoh T, Kitano M, Tabata K, Komori S, Ikeda M, et al. High-dose-rate brachytherapy and hypofractionated external beam radiotherapy combined with long-term hormonal therapy for high-risk and very-high-risk prostate cancer: outcomes after 5-year follow-up. J Radiat Res. 2014;55(3):509–17.

  40. Jain S, Hirst DG, O’Sullivan JM. Gold nanoparticles as novel agents for cancer therapy. Br J Radiol. 2012;85(10):101–13.

  41. Kaplan ID, Childs S, Pacold ME, Holupka E. MRI and ultrasound fusion images to focal guide salvage prostate brachytherapy for local recurrence after external beam radiation therapy: toxicity and outcomes. ABSTRACT. 2010 Genitourinary Cancers Symposium. 2010.

  42. Kaplan I, Oldenburg NE, Meskell P, Blake M, Church P, Holupka EJ. Real time MRI-ultrasound image guided stereotactic prostate biopsy. Magn Reson Imaging. 2002;20(3):295–9.

  43. Kim CK, Park BK, Kim B. Diffusion-weighted MRI at 3T for the evaluation of prostate cancer. Am J Roentgenol. 2010;194(6):1461–9.

  44. Kitajima K, Kaji Y, Fukabori Y, Yoshida K, Suganuma N, Sugimura K. Prostate cancer detection with 3T MRI: comparison of diffusion-weighted imaging and dynamic contrast-enhanced MRI in combination with T2-weighted imaging. J Magn Reson Imaging. 2010;31(3):625–31.

  45. Kobus T, Wright AJ, Scheenen TW, Heerschap A, et al. Mapping of prostate cancer by 1H MRSI. NMR Biomed. 2014;27(1):39–52.

  46. Koutrouvelis P, Lailas N, Katz S, Goldson A, Gilmontero G, Bondy H, et al. High- and low-risk prostate cancer treated with 3D CT-guided brachytherapy: 1-to 5-year follow-up. J Endourol. 2000;14(4):357–66.

  47. Kumar R, Korideck H, Ngwa W, Berbeco RI, Makrigiorgos GM, et al. Third generation gold nanoplatform optimized for radiation therapy. Transl Cancer Res. 2013; 2(4). doi: 10.3978/j.issn.2218-676X.2013.07.02.

  48. Kuo N, Lee J, Tempany C, Stuber M, Prince J. MRI-based prostate brachytherapy seed localization. Proc IEEE Int Symp Biomed Imaging. 2010;2010:1397–1400.

  49. Kurhanewicz J, Swanson MG, Nelson SJ, Vigneron DB. Combined magnetic resonance imaging and spectroscopic imaging approach to molecular imaging of prostate cancer. J Magn Reson Imaging. 2002;16(4):451–63.

  50. Lawrentscuk N, Fleshner N. The role of magnetic resonance imaging in targeting prostate cancer in patients with previous negative biopsies and elevated prostate-specific antigen levels. BJU Int. 2009;103(6):730–3.

  51. Le Duc G, Roux S, Paruta-Tuarez A, Dufort S, Brauer E, Marais A, et al. Advantages of gadolinium based ultrasmall nanoparticles vs molecular gadolinium chelates for radiotherapy guided by MRI for glioma treatment. Cancer Nanotechnol. 2014;5(4):1–14.

  52. Lechtman E, Mashouf S, Chattopadhyay N, Keller BM, Lai P, Cai Z, et al. A monte carlo-based model of gold nanoparticle radiosensitization accounting for increased radiobiological effectiveness. Phys Med Biol. 2013;58(10):3075–87.

  53. Lee RW. Extreme hypofractionation for prostate cancer. Expert Rev Anitcancer Ther. 2009;9(1):61–5.

  54. Lim TY, Stafford RJ, Kudchadker RJ, Sankaranarayanapillai M, Ibbott G, Rao A, et al. MRI characterization of cobalt dichloride-N-acetyl cysteine (C4) contrast agent marker for prostate brachytherapy. Phys Med Biol. 2014;59(10):2505–16.

  55. Maeda Y, Tabata H, Kawai T. Two-dimensional assembly of gold nanoparticles with a DNA network template. Appl Phys Lett. 2001;79:1181.

  56. Maneti G, Nezzo M, Chegai F, Vasili E, Bonanno E, Simonetti G. DWI of prostate cancer: optimal b-value in clinical practice. Prostate Cancer. 2014. doi:10.1155/2014/868269.

  57. Marks L, Young S, Natarajan S. MRI-ultrasound fusion for guidance of targeted biopsy. Curr Opin Urol. 2013a;23(2):43–50.

  58. Marks L, Young S, Natarajan S. MRI-ultrasound fusion for guidance of targeted prostate biopsy. Curr Opin Urol. 2013b;23(1):43–50.

  59. Martinez AA, Demanes J, Vargas C, Schour L, Ghilezan M, Gustafson GS. High-dose-rate prostate brachytherapy: an excellent accelerated-hypofractionated treatment for favorable prostate cancer. Am J Clin Oncol. 2010;33(5):481–8.

  60. Mayer A, Zholkover A, Portnoy O, Raviv G, Konen E, Symon Z, et al. Deformable registration of trans-rectal ultrasound (TRUS) and magnetic resonance imaging (MRI) for focal prostate brachytherapy. Intl J Com Ass Radiol Surg. 2016;26:1–9.

  61. Menard C, Susil RC, Choyke P, Gustafson GS, Kammerer W, Ning H, et al. MRI-guided HDR prostate brachytherapy in standard 1.5T scanner. Int J Radiat Oncol Biol Phys. 2004;59(5):1414–23.

  62. Merrick GS, Butler WM, Dorsey AT, Lief JH. The dependence of prostate postimplant dosimetric quality on CT volume determination. Int J Radiat Oncol Biol Phys. 1999;44(5):1111–7.

  63. Metcalfe PE, Liney GP, Holloway L, Walker A, Barton M, Delaney GP. The potential for an enhanced role for MRI in radiation-therapy treatment planning. Technol Cancer Res Treat. 2013;12(5):429–46.

  64. Morris WJ, Tyldesley S, Pai HH, Halperin R, McKenzie MR, Duncan G, et al. ASCENDE-RT: a multicenter, randomized trial of dose-escalated external beam radiation therapy (EBRT-B) versus low-dose-rate brachytherapy (LDR-B) for men with unfavorable-risk localized prostate cancer. J Clin Oncol. 2015a;33:S7.

  65. Morris WJ, Tyldesley S, Pai HH, Halperin R, McKenzie MR, Duncan G, et al. Low-dose-rate brachytherapy is superior to dose-escalated EBRT for unfavourable risk prostate cancer: the results of the ASCENDE-RT randomized control trial. Brachytherapy. 2015b;14(S1):S12.

  66. Muller BG, Futterer JJ, Gupta RT, Katz A, Kirkham A, Kurhanewicz J, et al. The role of magnetic resonance imaging (MRI) in focal therapy for prostate cancer: recommendations from a consensus panel. BJU Int. 2014;113(2):218–27.

  67. Nag S, Bice W, DeWyngaert K, Prestidge B, Stock R, Yu Y. The American brachytherapy society recommendations for permanent prostate brachytherapy postimplant dosimetric analysis. Int J Radiat Oncol Biol Phys. 2000;46(1):221–30.

  68. Nath R, Bice WS, Butler WM, Chen Z, Meigooni AS, Narayana V, et al. AAPM recommendations on dose prescription and reporting methods for permanent interstitial brachytherapy for prostate cancer: report of the American association of physicists in medicine task group no. 137. Med Phys. 2009;36(11):5310–22.

  69. Ngawa W, Korideck H, Kassis AI, Kumar R, Sridhar S, Makrigiorgos GM, et al. In vitro radiosensitization by gold nanoparticles during continuous low-dose-rate gamma irradiation with I-125 brachytherapy seeds. Nanomedicine. 2013;9(1):25–7.

  70. Norberg M, Egevad L, Holmberg L, Sparen P, Norlen BJ, Busch C. The sextant protocol for ultrasound-guided core biopsies of the prostate underestimates the presence of cancer. Urology. 1997;50(4):562–6.

  71. Panebianco V, Barchetti F, Sciarra A, Ciardi A, Indino EL, Papalia R, et al. Multiparametric magnetic resonance imaging vs. standard care in men being evaluated for prostate cancer: a randomized study. Urol Oncol. 2013;33(1):17 (e1–7).

  72. Perrault SD, Walkey C, Jennings T, Fischer HC, Chan WC. Mediating tumor targeting efficiency of nanoparticles through design. Nano Lett. 2009;9(5):1909–15.

  73. Picket B, Kurhanewicz J, Coakley F, Shinohara K, Fein B, Roach M III. Use of MRI and spectroscopy in evaluation of external beam radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2004;60(4):1047–55.

  74. Potters L, Cao Y, Calugaru E, Torre T, Fearn P, Wang XH. A comprehensive review of CT-based dosimetry parameters and biochemical control in patients treated with permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2001;50(3):605–14.

  75. Pouliot J, Yongbok K, Lessard E, Hsu I, Vigneror DB, Kurhanewicz J. Inverse planning for HDR prostate brachytherapy used to boost dominant intraprostatic lesions defined by magnetic resonance spectroscopy imaging. Int J Radiat Oncol Biol Phys. 2004;59(4):1196–207.

  76. Pullini S, Signor MA, Pancot M, Zuiani C, Bazzocchi M, Fongione S, et al. Impact of multiparametric magnetic resonance imaging on risk group assessment of patients with prostate cancer addressed to external beam radiation therapy. Eur J Radiol. 2016;85(4):764–70.

  77. Rahman WN, Bishara N, Ackerly T, He CF, Jackson P, Wong C, et al. Enhancement of radiation effects by gold nanoparticles for superficial radiation therapy. Nanomedicine. 2009;5(2):136–42.

  78. Rischke HC, Nestle U, Fechter T, Doll C, Volegova-Neher N, Henne K, et al. 3 tesla multiparametric MRI for GTV-definition of dominant intraprostatic lesions in patients with prostate cancer—an interobserver variability study. Radiat Oncol. 2013;8:183.

  79. Ritter M, Forman J, Kupelian P, Lawton C, Petereit D. Hypofractionation for prostate cancer. Cancer J. 2011;15(1):1–6.

  80. Roeske JC, Nunez L, Hoggarth M, Labay E, Weichselbaum RR. Characterization of the theoretical radiation dose enhancement from nanoparticles. Technol Cancer Res Treat. 2007;6(5):395–401.

  81. Sanfilippo NS, Cooper BT. Hypofractionated radiation therapy for prostate cancer: biologic and technical considerations. Am J Clin Exp Urol. 2014;2(4):286–93.

  82. Scheenen TW, Rosenkrantz AB, Haider MA, Futterer JJ. Multiparametric magnetic resonance imaging in prostate cancer management: current status and future perspectives. Invest Radiol. 2015;50(9):594–600.

  83. Singanamalli A, Rusu M, Sparks RE, Shih NN, Ziober A, Wang LP, et al. Identifying in vivo DCE MRI markers associated with microvessel architecture and gleason grades of prostate cancer. J Magn Reson Imaging. 2016;43(1):149–58.

  84. Solhjem MC, Davis BJ, Pisansky TM, Wilson TM, Mynderse LA, Herman MG, et al. Prostate volume measurement by transrectal ultrasound and computed tomography before and after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2004;60(3):767–76.

  85. Sparks R, Bloch BN, Feleppa E, Barratt D, Madabhushi A, et al. Fully automated prostate magnetic resonance imaging and transrectal ultrasound fusion via a probabilistic registration metric. Proc SPIE Int Soc Opt Eng. 2013;8:8671. doi:10.1117/12.2007610.

  86. Spiers FW. The influence of energy absorption and electron range on dosage in irradiated bone. Br J Radiol. 1949;22:521–33.

  87. Steenbergen P, Haustermans K, Lerut E, Oyen R, DeWever L, Van den Bergh L, et al. Prostate tumor delineation using multiparametric magnetic resonance imaging: inter-observer variability and pathology validation. Radiother Oncol. 2015;115(2):186–90.

  88. Steuten LMG, Retel VP. Comparative cost/QALY of guideline-recommended prostate cancer treatments: a UK cost perspective. 2nd ESTRO Forum. PD-0371:S145. 2013.

  89. Stone NN, Stock RG. Long-term urinary, sexual, and rectal morbidity in patients treated with iodine-125 prostate brachytherapy followed up for a minimum of 5 years. Urology. 2007;69(2):338–42.

  90. Susil RC, Camphausen K, Choyke P, McVeigh ER, Gustafson GS, Ning H, et al. System for prostate brachytherapy and biopsy in a standard 1.5T MRI scanner. Magn Reson Med. 2004;52(3):683–7.

  91. Thomadsen B, Venselaar J, Li Z. Physics and clinical aspects of brachytherapy. In: Levitt SH, editor. Technical basis of radiation therapy. Berlin: Springer-Verlag; 2012. p. 255–90.

  92. Thomas SD, Wachowicz K, Fallone BG. MRI of prostate brachytherapy seeds at high field: a study in phantom. Med Phys. 2009;36(11):5228–34.

  93. Tokuda J, Tuncali K, Iordachita I, Song SE, Federov A, Oguro S, et al. In-bore setup and software for 3T MRI-guided transperineal biopsy. Phys Med Biol. 2012;57(18):5823–40.

  94. Tselis N, Tunn UW, Chatzikonstantinou G, Milickovic N, Baltas D, Ratka M, et al. High dose rate brachytherapy as monotherapy for localized prostate cancer: a hypofractionated two-implant approach in 351 consecutive patients. Radiat Oncol. 2013;8:115. doi:10.1186/1748-717X-8-115.

  95. Vartholomeos P, Fruchard M, Ferreira A, Mavroidis C. MRI-guided nanorobotics systems for therapeutic and diagnostic applications. Ann Rev Biomed Eng. 2011;14:157–84.

  96. Verma S, Turkbey B, Muradyan N, Rajesh A, Cornud F, Haider MA, et al. Overview of dynamic contrast-enhanced MRI in prostate cancer diagnosis and management. Am J Roent. 2012;198:1277–88.

  97. Vogelius IR, Bentzen SM. Meta-analysis of the alpha/beta ratio for prostate cancer in the presence of an overall time factor: bad news, good news, or no new? Int J Radiat Oncol Biol Phys. 2013;85(1):89–94.

  98. Wallace T, Avital I, Stojadinovic A, Brucher BLDM, Cote E, Yu J. Multiparametric MRI-directed focal salvage permanent interstitial brachytherapy for locally recurrent adenocarcinoma of the prostate: a novel approach. J Cancer. 2013;4(2):146–51.

  99. Weinreb JC, Barentsz JO, Choyke PL, Cornud F, Haider MA, Macura KJ, et al. PI-RADS prostate imaging—reporting and data system: 2015, version 2. Eur Urol. 2016;69:16–40.

  100. Westphalen AC, Coakley FV, Qayyum A, Swanson M, Simko JP, Lu Y, et al. Peripheral zone prostate cancer: accuracy of different interpretative approaches with MR and MR spectroscopic imaging 1. Radiology. 2008;246(1):177–84.

  101. Wu X, Zhang F, Chen R, Zheng W, Yang X. Recent advances in imaging-guided interventions for prostate cancers. Cancer Lett. 2014;349:114–9.

  102. Xue J, Waterman F, Handler J, Gressen E. The effect of interobserver variability on transrectal ultrasonography-based postimplant dosimetry. Brachytherapy. 2006;5(3):174–82.

  103. Yamada Y, Rogers L, Demanes DJ, Morton G, Prestidge BR, Pouliot J, et al. American Brachytherapy society consensus guidelines for high-dose-rate prostate brachytherapy. Brachytherapy. 2012;11(1):20–32.

  104. Yoshioka Y, Konishi K, Sumida I, Takahashi Y, Isohashi F, Ogata T, et al. Monotherapeutic high-dose-rate brachytherapy for prostate cancer: five-year results of an extreme hypofractionation regimen with 54 Gy in nine fractions. Int J Radiat Oncol Biol Phys. 2011;80(2):469–75.

  105. Yu Y, Anderson LL, Li Z, Mellenberg D, Nath R, Schell MC, et al. Permanent prostate seed implant brachytherapy: report of the American association of physicists in medicine task group no. 64. Med Phys. 1999;26(10):2054–76.

  106. Zhang X, Xing JZ, Chen J, Ko L, Amanie J, Gulvita S, et al. Enhanced radiation sensitivity in prostate cancer by gold-nanoparticles. Clin Invest Med. 2008;31:E160.

  107. Zheng Y, Hunting DJ, Ayotte P, Sanche L. Radiosensitization of DNA by gold nanoparticles irradiated with high-energy electrons. Radiat Res. 2008;169(1):19–27.

Download references

Authors’ contributions

AN performed the literature review, drafted the manuscript, obtained the figures, and was involved in the iterative editing process. AR developed the structure, edited the manuscript, and provided expertise on MR-guided prostate brachytherapy; AR also was involved in selecting high-quality MRI images for dissemination. NV provided expertise on MRSI and supporting figures. All authors contributed to editing and revising the manuscript for the final preparation. All authors read and approved the final manuscript.

Acknowledgements

No additional acknowledgements.

Competing interests

The authors declare that they have no competing interests.

Author information

Affiliations

  1. Odette Cancer Centre, Sunnybrook Health Sciences Centre, 2075 Bayview Ave, Toronto, ON, M4N3M5, Canada
    • Alexandru Mihai Nicolae
    •  & Ananth Ravi
  2. Saskatoon Cancer Centre, 20 Campus Drive, Saskatoon, SK, S7N4H4, Canada
    • Niranjan Venugopal
Authors
  1. Search for Alexandru Mihai Nicolae in:
  2. Search for Niranjan Venugopal in:
  3. Search for Ananth Ravi in:

Corresponding author

Correspondence to Ananth Ravi.

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Nicolae, A.M., Venugopal, N. & Ravi, A. Trends in targeted prostate brachytherapy: from multiparametric MRI to nanomolecular radiosensitizers. Cancer Nano 7, 6 (2016). https://doi.org/10.1186/s12645-016-0018-5

Download citation

Keywords

  • Prostate cancer
  • Brachytherapy
  • Dose escalation
  • Hypofractionation
  • Multiparametric MRI
  • Gold nanoparticles
  • Dominant intraprostatic lesion

Cancer Nanotechnology

ISSN: 1868-6966

Contact us